Recommendations for improving clinical trial design to facilitate the study of youth-onset type 2 diabetes

Abstract

Background

The prevalence of type 2 diabetes is increasing in youths and differs from adult-onset type 2 diabetes in its characteristics and progression. Currently, only two drugs are approved for youth-onset type 2 diabetes and many patients are not meeting glycemic targets. Clearly, there is an urgent need to complete clinical trials in youths with type 2 diabetes to increase the therapeutic choice for these patients. However, factors such as limited patient numbers, unwillingness of patients to participate in trials, failure to meet strict inclusion and exclusion criteria, and poor clinic attendance have limited the size and number of trials in this complicated patient demographic.

Recommendations

This is a narrative opinion piece on the design of clinical trials in youth-onset type 2 diabetes prepared by researchers who undertake this type of study in different countries. The review addresses possible ways to enhance trial designs in youth-onset type 2 diabetes to meet regulatory requirements, while minimizing the barriers to patients’ participation. The definition of adolescence, recruitment of sufficient patient numbers, increasing flexibility in selection criteria, improving convenience of trial visits, requirements of a control group, possible endpoints, and trial compliance are all considered. The authors recommend allowing extrapolation from adult data, using multiple interventional arms within future trials, broadening inclusion criteria, and focusing on endpoints beyond glucose control, among others, in order to improve the successful completion of more trials in this population.

Conclusions

Improvements in trial design will enable better recruitment and retention and thereby more evidence for treatment outcomes for youth-onset type 2 diabetes.

Keywords

Adolescent clinical trials as topic diabetes mellitus type 2/therapy health services needs and demand hypoglycemic agents/therapeutic use

Get full access to this article

View all access options for this article.

References

International Diabetes Federation. IDF diabetes atlas. 8th ed., http://diabetesatlas.org/resources/2017-atlas.html (2017, accessed 15 November 2018).

Mayer-Davis

Lawrence

Dabelea

et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med 2017; 376: 1419–1429.

Neu

Feldhahn

Ehehalt

et al. No change in type 2 diabetes prevalence in children and adolescents over 10 years: update of a population-based survey in South Germany. Pediatr Diabetes 2018; 19(4): 637–639.

Narasimhan

Weinstock

RS.

Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. Mayo Clin Proc 2014; 89(6): 806–816.

Nadeau

Anderson

Berg

et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care 2016; 39(9): 1635–1642.

American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care 2018; 41: S1–S2.

Schernthaner

GH.

Current treatment of type 2 diabetes. Internist (Berl) 2012; 53: 1399–1410.

U.S. Food and Drug Administration. How is diabetes treated in children?https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm276191.htm (2018, accessed 10 April 2018).

TODAY Study Group, Zeitler

Hirst

et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247–2256.

10.

Tamborlane

Haymond

Dunger

et al. Expanding treatment options for youth with type 2 diabetes: current problems and proposed solutions: a white paper from the NICHD Diabetes Working Group. Diabetes Care 2016; 39(3): 323–329.

11.

Pinto

Stafford

Wang

et al. Changes in diabetes medication regimens and glycemic control in adolescents and young adults with youth onset type 2 diabetes: the SEARCH for diabetes in youth study. Pediatr Diabetes. Epub ahead of print 15 May 2018. DOI: 10.1111/pedi.12691.

12.

Dudkowski

Tsai

Liu

et al. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Eur J Clin Pharmacol 2017; 73(3): 279–288.

13.

Klein

Battelino

Chatterjee

et al. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther 2014; 16(10): 679–687.

14.

Malloy

Capparelli

Gottschalk

et al. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther 2009; 31(4): 806–815.

15.

Gottschalk

Danne

Vlajnic

et al. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care 2007; 30(4): 790–794.

16.

ClinicalTrials.gov. NCT01179048. https://clinicaltrials.gov/ct2/show/NCT01179048

17.

Marso

Daniels

Brown-Frandsen

et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.

18.

Zinman

Wanner

Lachin

et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

19.

ClinicalTrials.gov. NCT01032629. https://clinicaltrials.gov/ct2/show/NCT01032629

20.

ClinicalTrials.gov. NCT01989754. https://clinicaltrials.gov/ct2/show/NCT01989754

21.

Neal

Perkovic

Matthews

DR.

Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.

22.

Gemmill

Brown

Nandagopal

et al. Clinical trials in youth with type 2 diabetes. Pediatr Diabetes 2011; 12: 50–57.

23.

Karres

Pratt

Guettier

et al. Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes. Diabetes Care 2014; 37(10): 2665–2667.

24.

Sawyer

The age of adolescence. Lancet Child Adolesc Health 2018; 2: 223–228.

25.

Tanner

JM.

Growth and maturation during adolescence. Nutr Rev 1981; 39: 43–55.

26.

Kelsey

Zeitler

PS.

Insulin resistance of puberty. Curr Diab Rep 2016; 16: 64.

27.

Dahl

Allen

Wilbrecht

et al. Importance of investing in adolescence from a developmental science perspective. Nature 2018; 554(7693): 441–450.

28.

Worthman

Trang

Dynamics of body time, social time and life history at adolescence. Nature 2018; 554(7693): 451–457.

29.

Chen

Lan

Hsu

et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a nationwide longitudinal study. Diabetes Care 2016; 39: 788–793.

30.

Harron

Feltbower

McKinney

et al. Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0-29 years in West Yorkshire, U.K., 1991-2006. Diabetes Care 2011; 34(3): 652–654.

31.

Sohal

Qian

et al. Diabetes in the young: a population-based study of South Asian, Chinese and White people. Diabet Med 2015; 32(4): 487–496.

32.

Enpr-EMA. Reflection paper on the use of extrapolation in the development of medicines for paediatrics—draft, https://www.ema.europa.eu/documents/scientific-guideline/draft-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf (2017, accessed 2 May 2018).

33.

U.S. Food and Drug Administration. Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans guidance for industry, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm360507.pdf (2016, accessed 15 November 2018).

34.

European Medicines Agency. Paediatric requirements for marketing-authorisation applications, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000088.jsp&mid=WC0b01ac0580925c3f (2018, accessed 15 Nov 2018)

35.

Tamborlane

Klingensmith

Crisis in care: limited treatment options for type 2 diabetes in adolescents and youth. Diabetes Care 2013; 36(6): 1777–1778.

36.

Karres

Tomasi

New medicines for type 2 diabetes in adolescents: many products, few patients. Expert Rev Clin Pharmacol 2013; 6(3): 227–229.

37.

Lipman

Ratcliffe

Cooper

et al. Population-based survey of the prevalence of type 1 and type 2 diabetes in school children in Philadelphia. J Diabetes 2013; 5(4): 456–461.

38.

Imperatore

Boyle

Thompson

et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012; 35: 2515–2520.

39.

Eurostat. Children and young people in the population, EU-28, 1994, 2004 and 2014 (1) BYIE15.png, http://ec.europa.eu/eurostat/statistics-explained/index.php/File:Children_and_young_people_in_the_population,_EU-28,_1994,_2004_and_2014_(%C2%B9)_BYIE15.png#file (2015, accessed 10 April 2018).

40.

Braveman

Gottlieb

The social determinants of health: it’s time to consider the causes of the causes. Public Health Rep 2014; 129(Suppl. 2): 19–31.

41.

Song

SH.

Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. BMJ Open Diabetes Res Care 2015; 3(1): e000044.

42.

Garg

Jack

Zuckerman

Addressing the social determinants of health within the patient-centered medical home: lessons from pediatrics. JAMA 2013; 309(19): 2001–2002.

43.

Craig

Jefferies

Dabelea

et al. ISPAD Clinical Practice Consensus Guidelines 2014. Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 2014; 15(Suppl. 20): 4–17.

44.

Farrell

Bethin

Klingensmith

et al. Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes. Pediatr Diabetes 2017; 18(7): 574–578.

45.

Zeitler

Tandon

et al. ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. Pediatr Diabetes 2014; 15(Suppl. 20): 26–46.

46.

Howie

SR.

Blood sample volumes in child health research: review of safe limits. Bull World Health Organ 2011; 89(1): 46–53.

47.

Veal

GJ.

Blood volumes in pediatric clinical trials: a review of current regulations and guidance for research studies. Clin Investig 2014; 4: 1005–1011.

48.

Emanuel

Miller

FG.

The ethics of placebo—controlled trials—a middle ground. N Engl J Med 2001; 345(12): 915–919.

49.

Jones

Arslanian

Peterokova

et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25(1): 89–94.

50.

Hannon

Arslanian

SA.

The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 2015; 1353: 113–137.

51.

Dagogo-Jack

Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6: 589–593.

52.

Beck

Connor

Mullen

et al. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017; 40(8): 994–999.

53.

Xing

Kollman

Beck

et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011; 13(3): 351–358.

54.

UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.

55.

DCCT Research Group, Nathan

Genuth

et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

56.

ACCORD Study Group, Gerstein

Miller

et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

57.

ADVANCE Collaborative Group, Patel

MacMahon

et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.

58.

Duckworth

Abraira

Moritz

et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129–139.

59.

Marso

Bain

Consoli

et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844.

60.

Moon

Won

KC.

Pancreatic alpha-cell dysfunction in type 2 diabetes: old kids on the block. Diabetes Metab J 2015; 39: 1–9.

61.

Adolescence research must grow up. Nature 2018; 554: 403.

62.

Jayaraman

Rieder

Matsui

DM.

Compliance assessment in drug trials: has there been improvement in two decades. Can J Clin Pharmacol 2005; 12(3): e251–e253.

63.

Smith

DL.

Patient nonadherence in clinical trials: could there be a link to postmarketing patient safety?

Ther Innov Regul Sci 2012; 46: 27–34.

64.

Leuchs

Zinserling

Schlosser-Weber

et al. Estimation of the treatment effect in the presence of non-compliance and missing data. Stat Med 2014; 33(2): 193–208.

65.

FDA Advisory Committee Meeting. FDA briefing document (NDA 202293), https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2013/December/dapagliflozin_AC_FDA_briefing.pdf

66.

ICH. Final concept paper: E9(R1): addendum to statistical principles for clinical trials on choosing appropriate estimands and defining sensitivity analyses in clinical trials, 2014, https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/E9__R1__Final_Concept_Paper_October_23_2014.pdf

67.

ICH. Final concept paper: E9(R1): addendum to statistical principles for clinical trials on choosing appropriate estimands and defining sensitivity analyses in clinical trials, 2017, https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical_en.pdf

68.

Akacha

Bretz

Ohlssen

et al. Estimands and their role in clinical trials. Stat Biopharm Res 2017; 9: 268–271.